Teesside, United Kingdom, May 2026 — The United Kingdom’s advanced
ArkBio has received NMPA approval for Aizhida, a new ADHD treatment for patients aged six and above, marking a key advancement in China’s neuropsychiatric drug landscape.
KAOHSIUNG CITY, Taiwan:AICEND advanced the science of wound healing and
Teesside, United Kingdom, May 2026 — The United Kingdom’s advanced
ArkBio has received NMPA approval for Aizhida, a new ADHD treatment for patients aged six and above, marking a key advancement in China’s neuropsychiatric drug landscape.
KAOHSIUNG CITY, Taiwan:AICEND advanced the science of wound healing and
© | All rights reserved.
